UK hits pharma companies with £266 million fines for overcharging health service

The UK’s Competition and Markets Authority has fined four drugmakers over £266 million for inflating the price of a life-saving drug by over 10,000% and preventing the entry of competing medicines.


Get unlimited access to all Global Competition Review content